Apellis Pharmaceuticals, Inc. (BIT:1APLS)
Italy
· Delayed Price · Currency is EUR 15.55
-1.89 (-10.82%)
At close: May 7, 2025
Apellis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 775.84 | 781.37 | 396.59 | 75.42 | 66.56 | 250.65 | Upgrade
|
| Revenue Growth (YoY) | 48.04% | 97.02% | 425.83% | 13.31% | -73.44% | - | Upgrade
|
| Cost of Revenue | 459.44 | 445.29 | 412.9 | 392.87 | 426.07 | 25.05 | Upgrade
|
| Gross Profit | 316.4 | 336.07 | -16.31 | -317.45 | -359.51 | 225.6 | Upgrade
|
| Selling, General & Admin | 500.89 | 501.05 | 500.82 | 277.16 | 176.77 | 139.4 | Upgrade
|
| Research & Development | 1.72 | - | - | - | - | 299.92 | Upgrade
|
| Operating Expenses | 502.61 | 501.05 | 500.82 | 277.16 | 176.77 | 439.32 | Upgrade
|
| Operating Income | -186.22 | -164.98 | -517.12 | -594.61 | -536.28 | -213.73 | Upgrade
|
| Interest Expense | -44.47 | -40.39 | -29.58 | -32.63 | -13.24 | -29.94 | Upgrade
|
| Interest & Investment Income | 12.13 | 12.77 | 20.93 | 8.91 | 0.42 | 4.16 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.84 | -2.17 | -0.73 | -0.29 | -96.31 | -103.53 | Upgrade
|
| EBT Excluding Unusual Items | -220.4 | -194.77 | -526.5 | -618.61 | -645.41 | -343.03 | Upgrade
|
| Other Unusual Items | -1.95 | -1.95 | - | -32.89 | -100.59 | - | Upgrade
|
| Pretax Income | -222.35 | -196.72 | -526.5 | -651.5 | -746 | -343.03 | Upgrade
|
| Income Tax Expense | 1.33 | 1.16 | 2.13 | 0.67 | 0.35 | 1.85 | Upgrade
|
| Net Income | -223.68 | -197.88 | -528.63 | -652.17 | -746.35 | -344.87 | Upgrade
|
| Net Income to Common | -223.68 | -197.88 | -528.63 | -652.17 | -746.35 | -344.87 | Upgrade
|
| Shares Outstanding (Basic) | 125 | 124 | 119 | 106 | 84 | 75 | Upgrade
|
| Shares Outstanding (Diluted) | 125 | 124 | 119 | 106 | 84 | 75 | Upgrade
|
| Shares Change (YoY) | 2.96% | 4.40% | 11.84% | 25.70% | 12.32% | 20.79% | Upgrade
|
| EPS (Basic) | -1.80 | -1.60 | -4.45 | -6.15 | -8.84 | -4.59 | Upgrade
|
| EPS (Diluted) | -1.80 | -1.60 | -4.45 | -6.15 | -8.84 | -4.59 | Upgrade
|
| Free Cash Flow | -8.41 | -88.27 | -595.51 | -515.27 | -564.23 | -165.91 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.71 | -5.02 | -4.86 | -6.68 | -2.21 | Upgrade
|
| Gross Margin | 40.78% | 43.01% | -4.11% | - | - | 90.01% | Upgrade
|
| Operating Margin | -24.00% | -21.11% | -130.39% | -788.38% | -805.67% | -85.27% | Upgrade
|
| Profit Margin | -28.83% | -25.32% | -133.29% | -864.70% | -1121.28% | -137.59% | Upgrade
|
| Free Cash Flow Margin | -1.08% | -11.30% | -150.16% | -683.18% | -847.66% | -66.19% | Upgrade
|
| EBITDA | -184.42 | -163.18 | -515.34 | -593.06 | -534.9 | -213.09 | Upgrade
|
| EBITDA Margin | -23.77% | -20.88% | -129.94% | - | - | -85.02% | Upgrade
|
| D&A For EBITDA | 1.8 | 1.8 | 1.78 | 1.55 | 1.38 | 0.64 | Upgrade
|
| EBIT | -186.22 | -164.98 | -517.12 | -594.61 | -536.28 | -213.73 | Upgrade
|
| EBIT Margin | -24.00% | -21.11% | -130.39% | - | - | -85.27% | Upgrade
|
| Revenue as Reported | 775.84 | 781.37 | 396.59 | 75.42 | 66.56 | 250.65 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.